Mangoceuticals faces an existential liquidity crisis characterized by a 25.96% year-over-year revenue decline and deeply negative operating margins that reached -46.1% in 2026Q1. The company's reliance on intangible goodwill, which comprises 96% of total asset...
Price trend, volume and key moving averages
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q2 2026Latest May 19, 2026 | -$0.22 vs — | $67,864 vs — |
Q2 2026 Apr 1, 2026 | $0.13 vs — | $94,360 vs — |
Q4 2025 Nov 14, 2025 | -$0.69 vs — | $84,246 vs — |
Q3 2025 Aug 14, 2025 | -$0.57 vs — | $168,109 vs — |
Chemed (NYSE: CHE - Get Free Report) and Mangoceuticals (NASDAQ: MGRX - Get Free Report) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, risk, profitability, valuation, dividends, institutional ownership and analyst recommendations. Volatility and Risk Chemed has a beta of 0.51, suggesting
LifeStance Health Group (NASDAQ: LFST - Get Free Report) and Mangoceuticals (NASDAQ: MGRX - Get Free Report) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, institutional ownership, profitability, valuation and earnings. Insider and Institutional Ownership 85.5% of LifeStance Health
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the merger of Mangoceuticals, Inc. (NASDAQ: MGRX) and Nuclea Energy Inc. Halper Sadeh encourages Mangoceuticals shareholders to click here to learn more about their rights and options or contact Daniel Sadeh or Zachary Halper free of charge at (212) 763-0060 or [email protected] or [email protected]. The investigation concerns whether Mangoceuticals and its board of directors violated the federa.
The acquisition of Moltex brings over a decade of advanced nuclear R&D, backed by more than C$96 million in private investment and public funding from Canada and the U.S. Department of Energy. Asset-led transaction to add intellectual property and development materials related principally to the SSR-W advanced reactor and WATSS spent nuclear fuel recycling technologies.
Benchmark MGRX against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Mangoceuticals, Inc. (MGRX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $0.46 | $7.8M | -0.22 | -25.96% | -4526.86% | -141.66% | — | |
| $28.39 | $6.33B | 55.67 | 59% | -5.51% | -30.03% | — | |
| $42.79 | $3.23B | -20.77 | — | — | -102.48% | — | |
| $13.21 | $224.69M | -2.22 | -1.98% | -35.75% | -31.57% | — | |
| $6.13 | $1.11B | -5.38 | -1.54% | -7.13% | -13.08% | — | |
| $7.60 | $142.61M | 28.15 | 18.78% | 4.66% | 3.6% | — |
Mangoceuticals, Inc. (MGRX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Mangoceuticals, Inc. (MGRX) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 21, 2026·SEC
Aug 4, 2026·SEC
Jul 30, 2026·SEC
Get notified when MGRX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Mangoceuticals, Inc. (MGRX) stock FAQ — growth, dividends, profitability & financials explained
Mangoceuticals, Inc. (MGRX) reported $0.3M in revenue for fiscal year 2025.
Mangoceuticals, Inc. (MGRX) saw revenue decline by 26.0% over the past year.
Mangoceuticals, Inc. (MGRX) reported a net loss of $15.1M for fiscal year 2025.
Mangoceuticals, Inc. (MGRX) has a return on equity (ROE) of -141.7%. Negative ROE indicates the company is unprofitable.
Mangoceuticals, Inc. (MGRX) had negative free cash flow of $3.9M in fiscal year 2025, likely due to heavy capital investments.
